...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Phytomedicine : >Treatment effect and safety of EPs 7630-solution in acute bronchitis in childhood: report of a multicentre observational study.
【24h】

Treatment effect and safety of EPs 7630-solution in acute bronchitis in childhood: report of a multicentre observational study.

机译：EPs 7630溶液在儿童急性支气管炎中的治疗效果和安全性：一项多中心观察性研究的报告。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

An open post-marketing surveillance study was conducted to examine the treatment effect and safety of EPs 7630-solution in the treatment of acute bronchitis in children. This study included a total of 742 children (aged between 0 and 12 years) with acute bronchitis (83.4%) or acute exacerbations of chronic bronchitis (14.3%), who were treated with different doses of the herbal drug for up to 14 days. Five bronchitis specific symptoms (BSS) were summed up to give an overall measure of disease severity. Non-specific disease symptoms (loss of appetite, diarrhoea, headache, vomiting, and fever) were also recorded, together with adverse events and overall ratings of efficacy and tolerability. The overall BSS score decreased during treatment from 6.0+/-3.0 points at baseline to 2.7+/-2.5 points after 7 days and to 1.4+/-2.1 points after 14 days. Remission or improvement in at least 80% of patients was recorded for all the individual component symptoms. The proportion of patients suffering from non-specific symptoms also substantially improved during treatment. For example, loss of appetite was present in 65.8% of patients at study begin, but only in 27.6% at the time point of last observation visit. In 88.3% of cases, the responsible physician rated the treatment as successful. Adverse events were minor and transitory. In conclusion, EPs 7630-solution was shown to be a safe and an effective treatment option for acute bronchitis or acute exacerbations of chronic bronchitis in children.
机译：进行了一项公开的售后监督研究，以检查EPs 7630-溶液在儿童急性支气管炎治疗中的治疗效果和安全性。这项研究共纳入742名儿童（0至12岁），患有急性支气管炎（83.4％）或慢性支气管炎的急性加重（14.3％），他们接受了不同剂量的草药治疗长达14天。总结了五个支气管炎特异性症状（BSS），以总体上衡量疾病的严重程度。还记录了非特异性疾病症状（食欲不振，腹泻，头痛，呕吐和发烧），以及不良事件以及疗效和耐受性的总体评分。在治疗期间，总体BSS评分从基线的6.0 +/- 3.0分降低到7天后的2.7 +/- 2.5分和14天后的1.4 +/- 2.1分。记录到至少80％的患者症状缓解或改善。在治疗期间，患有非特异性症状的患者比例也大大提高。例如，研究开始时有65.8％的患者出现食欲不振，但在最后一次观察访视时仅有27.6％的患者出现食欲不振。在88.3％的情况下，负责的医师将治疗评定为成功。不良事件轻微且短暂。总之，EPs 7630溶液被证明是儿童急性支气管炎或慢性支气管炎急性加重的一种安全有效的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号